Evidence map›Paper›PMID 30525469›Full record

ArticleACS synthetic biology2018

Signal Transduction in Human Cell Lysate via Dynamic RNA Nanotechnology.

Lisa M Hochrein, Tianjia J Ge, Maayan Schwarzkopf, Niles A Pierce

Open access · greenAbstract read
In one paragraph

Article in ACS synthetic biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Lisa M Hochrein
Tianjia J Ge
Maayan Schwarzkopf
Niles A PierceWeatherall Institute of Molecular Medicine , University of Oxford , Oxford , OX3 9DS , United Kingdom.ORCID 0000-0003-2367-4406
California Institute of Technology · USUniversity of Oxford · GB

Funding

Engineering Triggered Nanomechanical TherapeuticsR01CA140759 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI PIERCE, NILES A · 2009 to 2013
$1.6M
NCI NIH HHS R01 CA140759
6 · The paper itself

Abstract

Dynamic RNA nanotechnology with small conditional RNAs (scRNAs) offers a promising conceptual approach to introducing synthetic regulatory links into endogenous biological circuits. Here, we use human cell lysate containing functional Dicer and RNases as a testbed for engineering scRNAs for conditional RNA interference (RNAi). scRNAs perform signal transduction via conditional shape change: detection of a subsequence of mRNA input X triggers formation of a Dicer substrate that is processed to yield small interfering RNA (siRNA) output anti-Y targeting independent mRNA Y for destruction. Automated sequence design is performed using the reaction pathway designer within NUPACK to encode this conditional hybridization cascade into the scRNA sequence subject to the sequence constraints imposed by X and Y. Because it is difficult for secondary structure models to predict which subsequences of mRNA input X will be accessible for detection, here we develop the RNAhyb method to experimentally determine accessible windows within the mRNA that are provided to the designer as sequence constraints. We demonstrate the programmability of scRNA regulators by engineering scRNAs for transducing in both directions between two full-length mRNAs X and Y, corresponding to either the forward molecular logic "if X then not Y" (X [Formula: see text] Y) or the reverse molecular logic "if Y then not X" (Y [Formula: see text] X). In human cell lysate, we observe a strong OFF/ON conditional response with low crosstalk, corresponding to a ≈20-fold increase in production of the siRNA output in response to the cognate versus noncognate full-length mRNA input. 2'OMe-RNA chemical modifications protect signal transduction reactants and intermediates against RNase degradation while enabling Dicer processing of signal transduction products. Because diverse biological pathways interact with RNA, scRNAs that transduce between detection of endogenous RNA inputs and production of biologically active RNA outputs hold great promise as a synthetic regulatory paradigm.

Indexed as

NanotechnologySignal TransductionDEAD-box RNA HelicasesHEK293 CellsHumansNucleic Acid HybridizationRibonuclease IIIRNA InterferenceRNA, MessengerRNA, Small InterferingSynthetic BiologyDEAD-box RNA HelicasesDICER1 protein, humanRibonuclease IIIRNA, MessengerRNA, Small Interferingconditional RNAiconditional siRNA productionDicer processingdynamic RNA nanotechnologyhuman cell lysatemolecular programmingRNA degradationsmall conditional RNA (scRNA)

Identifiers

PMID30525469
PMCPMC6305621
OpenAlexW2897791261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.